Destiny Pharma's CSO joins UK Covid-19 research and innovation taskforce

Clinical stage innovative biotechnology company Destiny Pharma said on Wednesday that chief scientific officer Dr Bill Love has joined the UK's Covid-19 Research and Innovation Taskforce.

Dr Love joined the Taskforce after UK Research and Innovation launched a funding call, inviting research and innovation proposals to address and mitigate the health, social, economic and environmental impacts of the Covid-19 pandemic.

The UKRI Taskforce provides advice and support in the delivery of the UKRI's Covid-19 research and innovation funding and will include the identification of future priorities and opportunities for research and innovation projects.

Dr Love said: "I am honoured to join the UKRI Taskforce, created to focus on the strength and creativity of the UK's world-class research base.

"I look forward to supporting UKRI in the identification of research and innovation projects to tackle this significant challenge worldwide."

As of 1030 GMT, Destiny Pharma shares were down 1.54% at 102.40p.